Biodesix, Inc. Provides Revenue Guidance for the Fourth Quarter Ended December 31, 2020
January 08, 2021 at 06:00 am
Share
Biodesix, Inc. provided revenue guidance for the fourth quarter ended December 31, 2020. For the quarter, the company expects preliminary unaudited revenue in a range of $25 million to $27 million as compared to $8.3 million a year ago, an increase of 201% to 225%.
Biodesix, Inc. (Biodesix) is a diagnostic solutions and services company. The Company develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.
BIODESIX, INC. 
